A Pilot Study of Autologous Ex Vivo Activated NK Cell Infusion in the Treatment of Metastatic Nasopharyngeal Carcinoma
We are investigating the use of immune cell therapy in metastatic Nasopharyngeal Cancer
(NPC). Recent small studies have shown that EBV specific cytotoxic T cells can be infused
into NPC patients with some good clinical effect including tumor responses. We are trying to
achieve a similar result using a less complex and less costly approach, with Natural Killer
(NK) cells. NK cells are known to recognize tumor and virally infected cells through a
variety of mechanisms. Also, NK cells influence the development of antigen-specific T cell
responses via reciprocal interactions with dendritic cells and the secretion of IFNγ.
This is a pilot clinical trial to study the feasibility of collecting, manipulating , and
infusing autologous enriched NK cells activated by short-term incubation in IL-2.
Leukapheresis units will be collected from eligible patients with NPC. NK cells will be
selected and activated with IL-2 prior to re-infusion. Patients will receive low dose IL-2
after infusion of activated NK cells. Post infusion monitoring will include peripheral blood
T cell subsets, cytokine secretion and serum cytokine levels. The parameters will be
correlated to clinical observations. If clinical efficacy is shown, our protocol could
represent a simple way of harnessing the immune system of the patient for treatment of this
disease. This study will also serve as platform technology development for later trials
involving manipulating cell therapy products.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment
Alvin Seng Cheong Wong, MBBS, MRCP
National University Hospital, Singapore
Singapore: Domain Specific Review Boards